Biotech stocks have been extremely popular among investors in 2020. Over the past year, the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) , an industry indicator, has returned over 33%, compared to the S&P 500 's 14% return during the same period. It's clear that a lot of eyes are on producers of testing supplies, drugs, and vaccines for the coronavirus.
The extraordinary attention paid to coronavirus stocks has left other top-notch biotechs out of the spotlight. I think that many of them are undervalued because of it. Let's look at why a blue chip drugmaker focused on rare diseases and a CRISPR gene-therapy developer have the potential to double your money.
Image Source: Getty Images.
For further details see:
2 Biotech Stocks That Could Double Your Money